BIOMUNE SYSTEMS INC
3, 2000-08-17
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: ALPNET INC, S-3, EX-23.3, 2000-08-17
Next: BIOMUNE SYSTEMS INC, SC 13D, 2000-08-17



FORM 3



U.S. SECURITIES AND EXCHANGE COMMISSION
      WASHINGTON, D.C.  20549                   --------------------------
       INITIAL STATEMENT OF                           OMB APPROVAL
  BENEFICIAL OWNERSHIP OF SECURITIES            --------------------------

                                                  OMB NUMBER:  3235-0104
                                                  EXPIRES:
                                                  SEPTEMBER 30, 1998
  Filed pursuant to Section 16(a) of the          ESTIMATED AVERAGE
    Securities Exchange Act of 1934,              BURDEN HOURS
   Section 17(a) of the Public Utility            PER RESPONSE 0.5
     Holding Company Act of 1935                --------------------------
  or Section 30(f) of the Investment
         Company Act of 1940

--------------------------------------------------------------------------
1.    Name and Address of Reporting Person

      Donlar Corporation
--------------------------------------------------------------------------
      (Last)                   (First)                  (Middle)

      6502 South Archer Avenue
--------------------------------------------------------------------------
                  (Street)

      Bedford Park             Illinois                 60501
--------------------------------------------------------------------------
      (City)                   (State)                  (Zip)

--------------------------------------------------------------------------
2.    Date of Event Requiring Statement (Month/Day/Year)

      08/07/00
--------------------------------------------------------------------------
3.    IRS OR SOCIAL SECURITY NUMBER OF REPORTING PERSON (VOLUNTARY)

--------------------------------------------------------------------------
4.    Issuer Name and Ticker or Trading Symbol

      Biomune Systems, Inc./BIME
--------------------------------------------------------------------------
5.    RELATIONSHIP OF REPORTING PERSON(S) TO ISSUER (CHECK ALL APPLICABLE)

( )   DIRECTOR
(X)   10% OWNER
( )   OFFICER (GIVE TITLE BELOW)
( )   OTHER (SPECIFY TITLE BELOW)
___________________________
--------------------------------------------------------------------------
6.    IF AMENDMENT, DATE OF ORIGINAL (MONTH/DAY/YEAR)

--------------------------------------------------------------------------
7.    INDIVIDUAL OR JOINT/GROUP FILING (CHECK APPLICABLE LINE)

(X)   FORM FILED BY ONE REPORTING PERSON
( )   FORM FILED BY MORE THAN ONE REPORTING PERSON



<PAGE>


==========================================================================
TABLE I - NON-DERIVATIVE SECURITIES BENEFICIALLY OWNED
---------------------------------------------------------------------------
1. TITLE OF SECURITY   2. AMOUNT OF     3. OWNERSHIP       4. NATURE
   (INSTR. 4)             SECURITIES       FORM DIRECT        INDIRECT
                          BENEFICIALLY     DIRECT (D)         BENEFICIAL
                          OWNED            OR INDIRECT        OWNERSHIP
                          (INSTR. 4)       (I) (INSTR. 5)     (INSTR.5)
---------------------------------------------------------------------------

Common Stock,
$0.0001 par value          2,136,554           (D)

==========================================================================
TABLE II - DERIVATIVE SECURITIES BENEFICIALLY OWNED
   (E.G., PUTS, CALLS, WARRANTS, OPTIONS, CONVERTIBLE SECURITIES)
--------------------------------------------------------------------------
1.  Title of Derivative Security (Instr. 4)

      None
--------------------------------------------------------------------------
2.  Date Exercisable and Expiration Date (Month/Day/Year)

___________________________                _________________________
   Date Exercisable                             Expiration Date
--------------------------------------------------------------------------
3.  Title and Amount of Securities Underlying Derivative Security (Instr.4)

_________________________________________        ___________________________
            Title                                Amount of Number of Shares
--------------------------------------------------------------------------
4.  Conversion or Exercise Price of Derivative Security

--------------------------------------------------------------------------
5.  Ownership Form of Derivative Security: Direct(D) or Indirect (I)
     (Instr.5)

--------------------------------------------------------------------------
6.  Nature of Indirect Beneficial Ownership (Instr. 5)

==========================================================================

EXPLANATION OF RESPONSES:





/s/ Lawrence P. Koskan
President and
Chief Executive Officer                                   August 17, 2000
____________________________________________            ___________________
**SIGNATURE OF REPORTING PERSON                                Date


___________________________________________
** INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACTS CONSTITUTE FEDERAL
   CRIMINAL VIOLATIONS.
   SEE 18 U.S.C. 1001 AND 15 U.S.C. 78FF(A).

NOTE:  FILE THREE COPIES OF THIS FORM, ONE OF WHICH MUST BE MANUALLY
SIGNED.  IF SPACE PROVIDED IS INSUFFICIENT, SEE INSTRUCTION 6 FOR
PROCEDURE.

POTENTIAL PERSONS WHO ARE TO RESPOND TO THE COLLECTION OF INFORMATION
CONTAINED IN THIS FORM ARE NOT REQUIRED TO RESPOND UNLESS THE FORM DISPLAYS
A CURRENTLY VALID OMB NUMBER.
==========================================================================


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission